Telenursing for the Early Detection and Management of Side Effects Associated With Cyclin-Dependent Kinase Inhibitors in Breast Cancer Patients
NCT07524829 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 124
Last updated 2026-04-13
Summary
This study is a multicenter randomized controlled trial designed to evaluate the effectiveness of a structured telenursing intervention in patients with breast cancer receiving cyclin-dependent kinase (CDK) inhibitor therapy.
Patients undergoing treatment with CDK inhibitors frequently experience adverse effects that may negatively impact treatment adherence, quality of life, and clinical outcomes. Early detection and timely management of these side effects are essential to optimize therapy and reduce complications, including unplanned hospitalizations and treatment interruptions.
In this study, participants are randomly assigned to one of two groups: standard care or standard care plus a structured telenursing follow-up program. The intervention consists of scheduled remote contacts (telephone or video consultations) conducted by trained nursing staff at predefined time points during treatment. These contacts aim to monitor symptoms, provide education, reinforce adherence, and facilitate early identification and management of treatment-related toxicities.
The primary objective of the study is to assess whether the telenursing intervention reduces the incidence and severity of treatment-related adverse events compared to standard care alone. Secondary objectives include evaluating its impact on emergency department visits, hospitalizations, treatment adherence, dose intensity, and patient-reported outcomes.
The study is currently recruiting participants across multiple centers. Results from this trial may provide evidence to support the integration of structured telenursing programs into routine oncology care, with the potential to improve patient safety, treatment continuity, and overall clinical outcomes.
Conditions
- Breast Cancer
- Drug-Related Side Effects and Adverse Reactions
- Chemotherapy Toxicity
- Treatment Adherence
- Treatment-Related Toxicity
Interventions
- BEHAVIORAL
-
Structured Telenursing Follow-up
A structured telenursing follow-up program consisting of scheduled telephone or video consultations conducted by trained oncology nurses during treatment with CDK inhibitors. The intervention includes systematic symptom assessment, patient education, adherence support, and early identification and management of treatment-related adverse events.
- OTHER
-
Standard Nursing Care
Routine clinical and nursing care provided according to standard local practice, including scheduled outpatient visits and patient-initiated contacts as needed.
Sponsors & Collaborators
-
Azienda Sanitaria Locale di Asti
lead OTHER_GOV
Principal Investigators
-
MANUELA CANICATTI', RN, MSc, PhD(c) · ASL AT
-
Michela PIREDDA, RN, MSc, PhD · University of Rome Tor Vergata, Italy
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-04-09
- Primary Completion
- 2028-04-30
- Completion
- 2028-09-30
Countries
- Italy
Study Locations
More Related Trials
-
Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors
NCT03837496 ·Status: COMPLETED ·Phase: NA
-
Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer
NCT00324259 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacist's Influence on Breast Cancer Patient Quality of Life
NCT02746666 ·Status: COMPLETED ·Phase: NA
-
Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole
NCT00316836 ·Status: COMPLETED
-
Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients
NCT00727883 ·Status: COMPLETED
-
Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer
NCT02400060 ·Status: COMPLETED ·Phase: NA
-
Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease
NCT00080756 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer
NCT04554927 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
NCT07019363 ·Status: RECRUITING ·Phase: PHASE3
-
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy
NCT02549430 ·Status: COMPLETED ·Phase: PHASE2
-
Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer
NCT04272801 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
NCT06044623 ·Status: RECRUITING ·Phase: PHASE3
-
Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer
NCT00086749 ·Status: COMPLETED
-
ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer
NCT04134598 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer
NCT00078832 ·Status: COMPLETED ·Phase: PHASE3
-
Therapeutic Education Intervention in Breast Cancer: PEPs Hormonotherapy
NCT02300675 ·Status: COMPLETED ·Phase: NA
-
Anastrozole and Letrozole
NCT00762294 ·Status: COMPLETED
-
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
NCT02314156 ·Status: COMPLETED ·Phase: PHASE2
-
Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Adherence and Clinical Outcome
NCT03761420 ·Status: COMPLETED
-
Compliance to a Hormone Therapy Regimen in Breast Cancer
NCT00666822 ·Status: COMPLETED
-
Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy
NCT00542594 ·Status: TERMINATED
-
Protocol for Women at Increased Risk of Developing Breast Cancer
NCT00291135 ·Status: COMPLETED ·Phase: PHASE2
-
Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor
NCT01765049 ·Status: ACTIVE_NOT_RECRUITING
-
The INTEGRATE Study: Integrated Pharmacogenetics, TDM and Active Pharmacovigilance as Innovative Tools for the Optimisation and Appropriateness of Drug Therapy
NCT06822959 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance
NCT05754528 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4